https://type1diabetesresearch.org.uk/wp-content/uploads/2023/04/marcelo-leal-taF3klwwAWA-unsplash.jpg5621000sopnzhttps://type1diabetesresearch.org.uk/wp-content/uploads/2023/02/logo.svgsopnz2023-04-10 20:41:112023-04-22 22:08:32Are we proof that a new drug to stop type 1 diabetes really does work?
The ELSA study launched nationally on World Diabetes Day in November 2022. Within 24 hours, over 1000 children were signed-up to the study! By February 2023, we have sent over 3000 home-testing kits out to families and have analysed over 1000 kits so far. The next phase of the study is to disseminate to schools and general practices across the UK. A huge thank you to the parents and children who have taken part in the ELSA study. If you would like to find out more about screening your child for type 1 diabetes, visit: https://www.elsadiabetes.nhs.uk/.
https://type1diabetesresearch.org.uk/wp-content/uploads/2023/03/ELSA-study-news.png359601sopnzhttps://type1diabetesresearch.org.uk/wp-content/uploads/2023/02/logo.svgsopnz2023-03-27 09:39:372023-03-27 09:39:37The ELSA Study
https://type1diabetesresearch.org.uk/wp-content/uploads/2023/03/pexels-nataliya-vaitkevich-6941101-web.jpg533800sopnzhttps://type1diabetesresearch.org.uk/wp-content/uploads/2023/02/logo.svgsopnz2023-03-09 09:09:052023-03-09 09:09:05Readily Available Drug Shows Promise in Treating Type 1 Diabetes
On 17/11/22 teplizumab was approved by the US Food and Drug Administration (FDA) as the first ever treatment indicated to delay the onset of stage 3 type 1 diabetes. This is the biggest treatment breakthrough for the condition since the discovery of insulin 100 years ago.
Although teplizumab is not approved in the UK yet, the US approval paves the way for this life-changing treatment to be made available to people at high risk of developing type 1 diabetes in the UK too.
https://type1diabetesresearch.org.uk/wp-content/uploads/2022/12/pexels-pavel-danilyuk-7653133.webp427640sopnzhttps://type1diabetesresearch.org.uk/wp-content/uploads/2023/02/logo.svgsopnz2022-12-12 23:44:012023-04-10 20:54:43First Treatment to Delay Type 1 Diabetes Licensed in the US
An 11 year old’s story of taking part in immunotherapy research: Mahn was diagnosed with type 1 diabetes in May 2020. His parents Sharon and Harj were determined to get him onto a clinical trial testing a new treatment called immunotherapy, which hopes to slow the immune attack behind type 1 diabetes. Please click the link to Mahn’s story where he shares his experience of his diagnosis, treatments and life with diabetes.
https://type1diabetesresearch.org.uk/wp-content/uploads/2020/12/Mahn4_resized_2.jpg11051512sopnzhttps://type1diabetesresearch.org.uk/wp-content/uploads/2023/02/logo.svgsopnz2020-12-16 11:57:162021-08-25 14:03:06Mahn’s story: taking part in immunotherapy research
Scientists and researchers are hoping to slow down the progression or prevent type one diabetes with immunotherapy treatments. This thought-provoking article from DUK’s Balance magazine explains how immunotherapy can help fight type 1 diabetes.
Delaying type 1 diabetes: an exciting breakthrough has been made by scientists in the trial of an immunotherapy drug that has been shown to delay a diagnosis of type 1 diabetes.
https://type1diabetesresearch.org.uk/wp-content/uploads/2018/01/Doctor-in-lab-Fun-Liu-e1516790818853.jpg439850sopnzhttps://type1diabetesresearch.org.uk/wp-content/uploads/2023/02/logo.svgsopnz2018-01-24 10:44:462021-08-25 14:03:19Multi-peptide Trial Aims to ‘Stall’ Type 1 Diabetes
https://type1diabetesresearch.org.uk/wp-content/uploads/2018/01/1st-injection-being-administered.jpg12001600sopnzhttps://type1diabetesresearch.org.uk/wp-content/uploads/2023/02/logo.svgsopnz2018-01-23 16:30:412021-08-25 14:03:19Pioneering Research for Type 1 Diabetes
We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
Google Analytics Cookies
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
Other external services
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
Other cookies
The following cookies are also needed - You can choose if you want to allow them:
Privacy Policy
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Are we proof that a new drug to stop type 1 diabetes really does work?
A new drug for Type 1 diabetes, Teplizumab, is being tested in the PROTECT clinical trial.
Teplizumab blocks the action of insulin-destroying antibodies in type 1.
Read the article on the Daily Mail
The ELSA Study
The ELSA study launched nationally on World Diabetes Day in November 2022. Within 24 hours, over 1000 children were signed-up to the study! By February 2023, we have sent over 3000 home-testing kits out to families and have analysed over 1000 kits so far. The next phase of the study is to disseminate to schools and general practices across the UK. A huge thank you to the parents and children who have taken part in the ELSA study. If you would like to find out more about screening your child for type 1 diabetes, visit: https://www.elsadiabetes.nhs.uk/.
Readily Available Drug Shows Promise in Treating Type 1 Diabetes
Study shows verapamil can have a beneficial effect on the pancreas in children with newly diagnosed type 1 diabetes.
Find out more from this article
First Treatment to Delay Type 1 Diabetes Licensed in the US
On 17/11/22 teplizumab was approved by the US Food and Drug Administration (FDA) as the first ever treatment indicated to delay the onset of stage 3 type 1 diabetes. This is the biggest treatment breakthrough for the condition since the discovery of insulin 100 years ago.
Although teplizumab is not approved in the UK yet, the US approval paves the way for this life-changing treatment to be made available to people at high risk of developing type 1 diabetes in the UK too.
Listen to this Podcast
Find out more
Mahn’s story: taking part in immunotherapy research
An 11 year old’s story of taking part in immunotherapy research: Mahn was diagnosed with type 1 diabetes in May 2020. His parents Sharon and Harj were determined to get him onto a clinical trial testing a new treatment called immunotherapy, which hopes to slow the immune attack behind type 1 diabetes. Please click the link to Mahn’s story where he shares his experience of his diagnosis, treatments and life with diabetes.
Visit the full story here >
Type 1 Diabetes Breakthrough
Scientists and researchers are hoping to slow down the progression or prevent type one diabetes with immunotherapy treatments. This thought-provoking article from DUK’s Balance magazine explains how immunotherapy can help fight type 1 diabetes.
Delaying type 1 diabetes: an exciting breakthrough has been made by scientists in the trial of an immunotherapy drug that has been shown to delay a diagnosis of type 1 diabetes.
Preserving Insulin production in people with newly diagnosed type 1 diabetes: progress made with drug aiming to boost insulin production in newly diagnosed type 1’s.
Multi-peptide Trial Aims to ‘Stall’ Type 1 Diabetes
Researchers at King’s College London and Guy’s and St Thomas’ hospital look into the possibility of slowing the progression of type 1 diabetes.
Link to news article with video: http://www.bbc.co.uk/news/health-35847271
Pioneering Research for Type 1 Diabetes
MonoPepT1De clinical trial for type 1 diabetes treatment shows promising results.
Link to news article: http://www.bbc.co.uk/news/health-40876438
Link to publication of results: http://stm.sciencemag.org/content/9/402/eaaf7779.full